Abstract

We investigated the value of tumor-infiltrating NK (TI-NK) cells and HLA class I tumor expression as biomarkers of response to neoadjuvant anti-HER2 antibody-based treatment in breast cancer. TI-NK cells and HLA-I were determined by IHC in pretreatment tumor biopsies from two cohorts of patients with HER2-positive breast cancer [discovery cohort (n = 42) and validation cohort (n = 71)]. Tumor-infiltrating lymphocytes (TIL) were scored according to international guidelines. Biomarker association with pathologic complete response (pCR) and disease-free survival (DFS) was adjusted for prognostic factors. Gene set variation analysis was used for determining immune cell populations concomitant to NK-cell enrichment in HER2-positive tumors from the Cancer Genome Atlas (n = 190). TI-NK cells were significantly associated with pCR in the discovery cohort as well as in the validation cohort (P < 0.0001), independently of clinicopathologic factors. A ≥3 TI-NK cells/50x high-power field (HPF) cutoff predicted pCR in the discovery and validation cohort [OR, 188 (11-3154); OR, 19.5 (5.3-71.8)]. Presence of TI-NK cells associated with prolonged DFS in both patient cohorts [HR, 0.07 (0.01-0.6); P = 0.01; HR, 0.3 (0.08-1.3); P = 0.1]. NK-, activated dendritic- and CD8 T-cell gene expression signatures positively correlated in HER2-positive tumors, supporting the value of NK cells as surrogates of effective antitumor immunity. Stratification of patients by tumor HLA-I expression identified patients with low and high relapse risk independently of pCR. This study identifies baseline TI-NK cells as an independent biomarker with great predictive value for pCR to anti-HER2 antibody-based treatment and points to the complementary value of tumor HLA-I status for defining patient prognosis independently of pCR.

Highlights

  • HER2 overexpression and/or HER2 gene amplification occur in approximately 15% to 20% of breast tumors and are associated with aggressive disease [1]

  • tumor-infiltrating Natural killer (NK) (TI-NK) cells were significantly associated with pathologic complete response (pCR) in the discovery cohort as well as in the validation cohort (P < 0.0001), independently of clinicopathologic factors

  • Presence of TI-NK cells associated with prolonged disease-free survival (DFS) in both patient cohorts [HR, 0.07 (0.01–0.6); P 1⁄4 0.01; HR, 0.3 (0.08–1.3); P 1⁄4 0.1]

Read more

Summary

Introduction

HER2 overexpression and/or HER2 gene amplification occur in approximately 15% to 20% of breast tumors and are associated with aggressive disease [1]. Combination of chemotherapy and anti-HER2 mAbs, trastuzumab as standalone or trastuzumab and pertuzumab, is the prevailing neoadjuvant approach for patients with primary HER2-positive breast cancer [2, 3]. A subgroup of patients presents excellent clinical outcomes to anti-HER2 mAbs in the absence of concomitant chemotherapy [2, 3]. This heterogeneity in clinical efficacy highlights: (i) the importance of further understanding the mechanisms of action underlying anti-HER2 mAb–based treatment efficacy in different patients, and (ii) the need for biomarkers aiding in patient stratification for tailoring treatment escalation or deescalation.

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call